IRAK4 and primary central nervous system lymphoma: There is an ongoing clinical trial of CA-4948 (an oral IRAK4 inhibitor) combined with ibrutinib (NCT03328078) in patients with R/R hematologic malignancies, of which part B included the newly diagnosed PCNSL and ibrutinib-resistance R/R PCNSL (123).